Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Artesunate overcomes the resistance of basal type of bladder cancer to RC48

ABSTRACT: Artesunate overcomes the resistance of basal type of bladder cancer to RC48

PROVIDER: PRJNA996609 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25339972_1.fastq.gz	Fastqsanger.gz
	SRR25339972_2.fastq.gz	Fastqsanger.gz
	SRR25339973_1.fastq.gz	Fastqsanger.gz
	SRR25339973_2.fastq.gz	Fastqsanger.gz
	SRR25339974_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Artesunate overcomes the resistance of basal type of bladder cancer to RC48

Project description:ERBB2 expression mediates sensitivity of bladder cancer cells to RC48. JAK/STAT3 pathways compensatory activation after exposing RC48. A combination of STAT3 inhibitor-artesunate and RC48 could significantly inhibit basal bladder cancer growth. These findings provided a theoretical foundation for subsequent individualized therapy for MIBC based on the molecular types.

2024-06-01 | GSE237789 | GEO

HIF1a inhibition overcomes castration resistance

Project description:HIF1a inhibition overcomes castration resistance

| PRJNA892463 | ENA

Rosiglitazone and Trametinib to treat basal bladder tumors [RNA-Seq]

Project description:To investigate the anti-tumor effect of Rosiglitazone+Trametinib in basal bladder cancer, we tested the drug combination in BBN-induced basal tumor mouse model in vivo and BBN-derived tumor cell line BBN963 in vitro.

2024-03-15 | GSE234326 | GEO

Rosiglitazone and Trametinib to treat basal bladder tumors [ATAC-Seq]

2024-03-15 | GSE234325 | GEO

Rosiglitazone and Trametinib to treat basal bladder tumors

Project description:Rosiglitazone and Trametinib to treat basal bladder tumors

| PRJNA980751 | ENA

Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer

Project description:Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer

| EGAS00001006334 | EGA

Loss of LPAR6 and CAB39L Dysregulate Basal to Luminal Urothelial Differentiation Program Contributing to Bladder Carcinogenesis

Project description:In vitro and in vivo studies including single cell sequencing showed that LPAR6 and CAB39L play a major role in regulating basal to luminal urothelial differentiation. Their loss of function contributed to bladder carcinogenesis by dysregulating urothelial differentiation program and sensitizing the urothelium to N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) induced cancers, which recapitulated luminal and basal subtypes of human bladder cancer.

2024-06-19 | GSE235455 | GEO

SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

Project description:SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

| PRJNA687056 | ENA

Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer

Project description:RNA-seq was used to identify basal and luminal subtypes in canine bladder cancer. In addition to larger gene-sets, a smaller panel of genes was developed to stratify canine samples into either basal or luminal subtype prospectively. Immune signature patterns were queried in basal and luminal subtypes.

2018-08-01 | GSE110661 | GEO

Rosiglitazone and Trametinib to treat basal bladder tumors [ATAC-Seq]

Project description:Rosiglitazone and Trametinib to treat basal bladder tumors [ATAC-Seq]

| PRJNA980830 | ENA